CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 100 target
Drug / intervention
High-dose immunoablative therapydrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00005778
NCT00005778Phase 3Completed

Randomized Trial of High-Dose IV Cyclophosphamide Versus Monthly IV Cyclophosphamide

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)·interventional·Posted Jun 5, 2000·Updated Nov 6, 2008

In Brief

A Phase 3 clinical trial evaluating High-dose immunoablative therapy for Lupus Erythematosus, Systemic. Completed, enrolled 100 participants across 3 sites.

Detailed Summary

This study compares the effectiveness of high-dose cyclophosphamide treatment with the "gold standard" treatment, monthly intravenous (IV) cyclophosphamide, in people with moderate to severe lupus that does not respond to high-dose corticosteroid therapy. We will give patients either IV cyclophosphamide (750 milligrams per square meter of body surface area) monthly for 6 months, followed by quarterly maintenance therapy, or high-dose IV cyclophosphamide (50 milligrams per kilogram body weight per day) for the first four days of the study. Patients will be followed for 24 months after therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 5, 2000
Enrollment StartJan 1, 2000
Primary CompletionApr 1, 2006
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 26.1 years ago

Interventions

High-dose immunoablative therapydrug

1. High dose cyclophosphamide for 4 days. 2. NIH monthly IV cytoxan for 6 months followed by quarterly for 2 years.